Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
151 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Attention Deficit Hyperactivity Disorder (ADHD) Overview 8 Therapeutics Development 9 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 9 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 10 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 11 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes 14 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 19 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 22 Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 23 DURECT Corporation 23 Eli Lilly and Company 24 Taisho Pharmaceutical Co., Ltd. 25 NeuroDerm Ltd. 26 Takeda Pharmaceutical Company Limited 27 Richter Gedeon Nyrt. 28 Pfizer Inc. 29 Purdue Pharma L.P. 30 Shire Plc 31 Vernalis plc 32 Collegium Pharmaceutical, Inc. 33 Hisamitsu Pharmaceutical Co., Inc. 34 Arbor Pharmaceuticals, LLC. 35 Curemark, LLC 36 Supernus Pharmaceuticals, Inc. 37 Intra-Cellular Therapies, Inc. 38 Tris Pharma, Inc. 39 Neos Therapeutics, Inc. 40 KemPharm, Inc. 41 Otsuka Holdings Co., Ltd. 42 Reviva Pharmaceuticals Inc. 43 Amarantus Bioscience Holdings, Inc. 44 Mnemosyne Pharmaceuticals, Inc. 45 Alcobra Ltd 46 Sunovion Pharmaceuticals Inc. 47 Signature Therapeutics, Inc 48 P2D Bioscience 49 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Target 51 Assessment by Mechanism of Action 54 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 60 amfetamine XR - Drug Profile 60 SHP-465 - Drug Profile 61 dasotraline - Drug Profile 62 methylphenidate hydrochloride - Drug Profile 63 guanfacine hydrochloride ER - Drug Profile 64 CM-4612 - Drug Profile 66 methylphenidate hydrochloride - Drug Profile 67 TRI-102 - Drug Profile 68 methylphenidate hydrochloride XR - Drug Profile 69 methylphenidate hydrochloride - Drug Profile 70 methylphenidate hydrochloride ER - Drug Profile 71 edivoxetine - Drug Profile 72 brexpiprazole - Drug Profile 74 dextroamphetamine - Drug Profile 76 eltoprazine - Drug Profile 77 lisdexamfetamine dimesylate - Drug Profile 78 SPN-812 - Drug Profile 82 ND-0801 - Drug Profile 83 Metadoxine ER - Drug Profile 84 AR-08 - Drug Profile 86 centanafadine SR - Drug Profile 87 dextroamphetamine MR - Drug Profile 88 V-81444 - Drug Profile 89 centanafadine - Drug Profile 90 PBF-509 - Drug Profile 91 IPX-233 - Drug Profile 92 TAK-137 - Drug Profile 93 COL-171 - Drug Profile 94 ITI-214 - Drug Profile 95 Small Molecule to Inhibit A2A Receptor for CNS Disorders - Drug Profile 96 PD-2005 - Drug Profile 97 PD-2007 - Drug Profile 98 KP-415 - Drug Profile 99 PFR-08001 - Drug Profile 100 MGS-0028 - Drug Profile 101 PFR-8026 - Drug Profile 102 BLI-1008 - Drug Profile 103 methylphenidate hydrochloride - Drug Profile 104 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 105 RP-14000 - Drug Profile 106 RGH-235 - Drug Profile 107 Small Molecule to Agonize NMDA2D for ADHD - Drug Profile 108 Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 109 Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimers Disease - Drug Profile 110 Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 111 Small Molecules to Antagonize Dopamine D4 Receptor for ADHD - Drug Profile 112 RP-5063 - Drug Profile 113 Small Molecule for ADHD - Drug Profile 114 etiguanfacine - Drug Profile 115 Drug for Attention Deficit Hyperactivity Disorder - Drug Profile 116 Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates 117 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 137 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 138 Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 139 Featured News & Press Releases 139 Appendix 147 Methodology 147 Coverage 147 Secondary Research 147 Primary Research 147 Expert Panel Validation 147 Contact Us 148 Disclaimer 148
List of Tables Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2014 12 Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Late Stage Development, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Comparative Analysis by Unknown Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H2 2014 26 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2014 27 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 28 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H2 2014 29 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 30 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Richter Gedeon Nyrt., H2 2014 31 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Pfizer Inc., H2 2014 32 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Purdue Pharma L.P., H2 2014 33 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2014 34 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vernalis plc, H2 2014 35 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 36 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 37 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC., H2 2014 38 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H2 2014 39 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H2 2014 40 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 41 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma, Inc., H2 2014 42 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H2 2014 43 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H2 2014 44 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 45 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 46 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 47 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 48 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2014 49 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 50 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Signature Therapeutics, Inc, H2 2014 51 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2014 52 Assessment by Monotherapy Products, H2 2014 53 Number of Products by Stage and Target, H2 2014 56 Number of Products by Stage and Mechanism of Action, H2 2014 59 Number of Products by Stage and Route of Administration, H2 2014 61 Number of Products by Stage and Molecule Type, H2 2014 62 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Recent Pipeline Updates, H2 2014 120 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2014 140 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2014 141
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.